Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc. develops biomedical products for women’s reproductive health, with news centered on fertility treatment, fallopian tube assessment, and non-surgical permanent birth control. Its portfolio includes FemaSeed intratubal insemination, FemaSeed Complete for in-office fertility care, FemVue for ultrasound-based fallopian tube evaluation, FemBloc permanent birth control, and related diagnostic products such as FemChec.
Recurring updates cover product commercialization in OB/GYN settings, international distribution and market access, regulatory approvals outside the United States, U.S. clinical and regulatory development for FemBloc, reimbursement-related developments, financing, operating results, and governance changes.
Femasys Inc. (NASDAQ: FEMY) has announced the commercial availability of FemCerv®, an innovative endocervical tissue sampler designed to improve tissue quality and quantity, enhancing women's healthcare. This new device aims to replace outdated products, providing a more comfortable and effective solution for tissue sampling during abnormal pap smear evaluations. Additionally, the company has bolstered its management team with the appointment of Michael Meier as Vice President of Sales and Marketing, who brings over 20 years of experience in medical device commercialization.
Femasys Inc. (NASDAQ: FEMY) announced that CEO Kathy Lee-Sepsick will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting at 7:00 AM ET on September 12.
The conference will feature a fireside chat format, and Femasys management will hold one-on-one meetings during the event. Femasys focuses on developing minimally invasive technologies for reproductive health, including FemBloc® for birth control and FemaSeed® for infertility.
Femasys Inc. (NASDAQ: FEMY) reported its financial results for Q2 and the first half of 2022, highlighting important advancements in women's reproductive health technologies. Revenue for the six months decreased by 4.8% to $624,518, with R&D expenses rising significantly by 53.1% to $2.9 million due to increased clinical costs. The net loss grew to $5.5 million, or $0.47 per share. Upcoming product launches, including FemCerv® and FemCath™, are expected by year-end. Enrollment for the FemBloc® study is on track, with an interim analysis for FemaSeed® due in Q4.
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's health, will hold one-on-one virtual meetings during the BTIG Biotechnology Conference on August 8-9, 2022, at the St. Regis New York Hotel. The company develops minimally invasive technologies for reproductive health, including its lead products, FemBloc® for permanent birth control and FemaSeed® for infertility. Interested participants are encouraged to contact their BTIG representative for scheduling.
Femasys Inc. (NASDAQ: FEMY) will host a significant webinar on July 28, 2022, at 10:30 AM EDT, featuring Dr. Paul D. Blumenthal, who will discuss the company's innovative FemBloc solution for permanent birth control. This event comes in response to the reversal of Roe v. Wade, emphasizing the unmet needs for permanent contraceptive options. FemBloc utilizes a unique delivery method that safely closes the fallopian tubes without surgery, aiming for confirmation of success within 90 days. A live Q&A session will follow the presentation.
Femasys Inc. (NASDAQ: FEMY) has been invited to present at the Women’s Health Panel Discussion hosted by Maxim Group LLC on July 13, 2022, at 11:00 a.m. ET. Kathy Lee-Sepsick, CEO, will discuss the implications of the Supreme Court's decision to overturn Roe v. Wade on women's health and contraception. This virtual event will spotlight the critical issues in women's reproductive health, bringing together key industry players. Femasys is known for its innovations in minimally invasive reproductive health technologies, including FemBloc and FemaSeed.
Femasys Inc. (NASDAQ: FEMY) announced the appointment of Charles Larsen as the new non-executive Chair of the Board, succeeding founder Kathy Lee-Sepsick. With over 40 years in the medical device industry, Larsen is expected to enhance corporate governance and aid Femasys in advancing its product candidates like FemBloc and FemaSeed. Kathy Lee-Sepsick emphasized Larsen's leadership experience and insight in strategic transformations as vital for the company's mission to improve women's health globally.
Femasys Inc. (NASDAQ: FEMY) announced that its CEO, Kathy Lee-Sepsick, will present at the LSX World Congress USA in Boston from June 21-22, 2022. She will lead a session on overcoming regulatory hurdles for women’s health products, focusing on FemaSeed and FemBloc. The Women’s Health CEO Forum will also feature her insights on industry collaboration. This event gathers leaders in biotech and medtech to drive innovation and growth in women's reproductive health.
Femasys Inc. (NASDAQ: FEMY) announced Q1 2022 financial results, reporting a net loss of $2.88 million or $0.24 per share. General and administrative expenses rose by 62.3% to $1.45 million, and R&D expenses increased by 42.8% to $1.42 million. Sales of FemVue® decreased by 2.5% to $321,405. Despite these challenges, Femasys is set to commercialize FemCerv® and FemCath™ by year-end and is making progress in clinical trials for FemBloc and FemaSeed. The company aims to enhance women's health solutions with its expanding product portfolio.
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, will participate in the 2022 Virtual Growth Conference from March 28-30. CEO Kathy Lee-Sepsick will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 from 3:00 pm to 4:30 pm ET. The conference will discuss innovations in women's health, highlighting Femasys's ongoing development of minimally invasive technologies, including FemBloc® and FemaSeed® for permanent birth control and infertility treatment respectively. For more details, registration is available online.